Advice

in the absence of a submission from the holder of the marketing authorisation:

glasdegib (Daurismo®) is not recommended for use within NHSScotland.

Indication under review: In combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (AML) in adult patients who are not candidates for standard induction chemotherapy.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.

Download detailed advice616KB (PDF)

Download

Medicine details

Medicine name:
glasdegib (Daurismo)
SMC ID:
SMC2341
Indication:

In combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (AML) in adult patients who are not candidates for standard induction chemotherapy.

Pharmaceutical company
Pfizer Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Non submission
Status
Not recommended
Date advice published
08 February 2021